stockrow
Friday 6 November 2026
Export MDGL’s income statement to Excel — free account
Madrigal Pharmaceuticals, Inc.
MDGL Healthcare Biotechnology
Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024.
- Revenue
- +50.1%
- EPS
- +147.3%
- Free cash flow
- +53.5%
- Total debt
- +0.45%
Quarter to September 2026, against a year earlier
394.25
5.85
−1.46%
Follow MDGL
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
10.32 | 12.19 | 13.42 | 13.63 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
122.27 | 670.81 | (90.77) | (97.89) | |
P/B ratio |
23.51 | 29.88 | 27.96 | 21.68 | |
Price to Tangible BV |
23.78 | 30.30 | 28.34 | 21.95 | |
EV/Sales |
9.89 | 11.80 | 13.00 | 12.95 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(89.93) | (76.63) | (54.90) | (65.50) | |
EV/FCF |
(82.26) | (72.40) | (53.41) | (64.00) | |
Quick Ratio |
2.62 | 2.76 | 2.97 | 3.62 | |
Current Ratio |
3.05 | 3.20 | 3.50 | 4.01 | |
Net Debt/EBITDA |
(10.75) | 9.09 | 5.22 | 11.34 | |
Debt/Assets |
23.79% | 27.38% | 27.73% | 26.98% | |
Debt/Equity |
0.54 | 0.65 | 0.63 | 0.56 | |
Asset Turnover |
1.02 | 1.14 | 1.02 | 0.83 | |
Operating CF/Net income |
2.17 | (0.40) | 1.77 | 2.28 | |
Capex/Depreciation |
(2.27) | (2.85) | (3.10) | 0.16 | |
Interest Coverage |
6.94 | (7.09) | (11.86) | (7.18) | |
Research and Development Expense of Revenue |
16.64% | 25.03% | 34.91% | 36.21% | |
Selling, General and Administrative Expense of Revenue |
61.61% | 79.44% | 86.25% | 74.74% | |
Intangible Assets out of Total Assets |
0.00 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
9.03% | 9.71% | 10.93% | 8.03% | |
Graham Net Nets |
0.04 | 0.03 | 0.03 | 0.05 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1.17%) | (2.20%) | (2.16%) | (1.83%) | |
Free Cash Flow Yield |
(1.16%) | (1.34%) | (1.81%) | (1.48%) | |
Revenue per Share |
14.75 | 12.50 | 10.72 | 14.31 | |
Operating CF per Share |
4.12 | 0.80 | (5.77) | (5.95) | |
Capex per Share |
(0.13) | (0.15) | (0.13) | 0.02 | |
Free Cash Flow per Share |
3.99 | 0.65 | (5.90) | (5.93) | |
Cash per Share |
32.88 | 28.78 | 28.17 | 44.07 | |
Shareholders Equity per Share |
21.44 | 17.97 | 18.72 | 26.87 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
21.44 | 17.97 | 18.72 | 26.87 | |
Free Cash Flow |
116.63 | 19.08 | (171.28) | (133.07) | |
Working Capital |
932.87 | 824.98 | 844.05 | 935.48 | |
Capital Expenditures |
(3.93) | (4.25) | (3.85) | 0.39 | |
Net Current Asset Value |
579.66 | 478.26 | 498.43 | 588.87 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
170.33 | 135.77 | 124.39 | 94.15 | |
Average Payables |
53.15 | 36.24 | 51.43 | 46.24 | |
Average Inventory |
95.95 | 81.44 | 83.66 | 54.45 | |
Average Assets |
1,398.42 | 1,130.01 | 1,111.98 | 1,150.92 | |
Average Common Equity |
626.34 | 609.85 | 627.05 | 678.54 |
Columns are period end dates · fundamentals updated 5 Nov 2026